Cargando…

Association between oligo-residual disease and patterns of failure during EGFR-TKI treatment in EGFR-mutated non-small cell lung cancer: a retrospective study

BACKGROUND: Local ablative therapy (LAT) may be beneficial for patients with epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer (NSCLC) with oligo-residual disease after treatment with EGFR tyrosine kinase inhibitor (EGFR-TKI). However, this has not been fully established. Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Miyawaki, Taichi, Kenmotsu, Hirotsugu, Kodama, Hiroaki, Nishioka, Naoya, Miyawaki, Eriko, Mamesaya, Nobuaki, Kobayashi, Haruki, Omori, Shota, Ko, Ryo, Wakuda, Kazushige, Ono, Akira, Naito, Tateaki, Murakami, Haruyasu, Mori, Keita, Harada, Hideyuki, Endo, Masahiro, Takahashi, Kazuhisa, Takahashi, Toshiaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8605535/
https://www.ncbi.nlm.nih.gov/pubmed/34798865
http://dx.doi.org/10.1186/s12885-021-08983-2
_version_ 1784602201362006016
author Miyawaki, Taichi
Kenmotsu, Hirotsugu
Kodama, Hiroaki
Nishioka, Naoya
Miyawaki, Eriko
Mamesaya, Nobuaki
Kobayashi, Haruki
Omori, Shota
Ko, Ryo
Wakuda, Kazushige
Ono, Akira
Naito, Tateaki
Murakami, Haruyasu
Mori, Keita
Harada, Hideyuki
Endo, Masahiro
Takahashi, Kazuhisa
Takahashi, Toshiaki
author_facet Miyawaki, Taichi
Kenmotsu, Hirotsugu
Kodama, Hiroaki
Nishioka, Naoya
Miyawaki, Eriko
Mamesaya, Nobuaki
Kobayashi, Haruki
Omori, Shota
Ko, Ryo
Wakuda, Kazushige
Ono, Akira
Naito, Tateaki
Murakami, Haruyasu
Mori, Keita
Harada, Hideyuki
Endo, Masahiro
Takahashi, Kazuhisa
Takahashi, Toshiaki
author_sort Miyawaki, Taichi
collection PubMed
description BACKGROUND: Local ablative therapy (LAT) may be beneficial for patients with epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer (NSCLC) with oligo-residual disease after treatment with EGFR tyrosine kinase inhibitor (EGFR-TKI). However, this has not been fully established. This study aimed to evaluate the predominant progressive disease (PD) pattern limited to residual sites of disease after treatment with EGFR-TKI. METHODS: Patients with advanced EGFR-mutated NSCLC treated with EGFR-TKIs as first-line therapy were retrospectively analysed during a 7-year period. Oligo-residual disease was defined as the presence of 1 – 4 lesions (including the primary site) at 3 months from the start of EGFR-TKI treatment. The predictive factors of PD patterns after EGFR-TKI treatment were evaluated. RESULTS: A total of 207 patients were included. Three months after the start of EGFR-TKI treatment, 66 patients (32%) had oligo-residual disease. A total of 191 patients had PD, 60 with oligo-residual disease and 131 with non-oligo-residual disease. Regarding the pattern, 44 patients (73%) with oligo-residual disease and 37 patients (28%) with non-oligo-residual disease had PD limited to the residual sites. Multivariate logistic regression analysis at 3 months from the start of EGFR-TKI treatment revealed that oligo-residual disease (P < 0.001), the lack of residual central nervous system metastases (P = 0.032), and initial treatment with osimertinib (P = 0.028) were independent predictors of PD limited to residual disease sites. CONCLUSIONS: This study provided a rationale for LAT to all sites of residual disease in patients with oligo-residual disease during EGFR-TKI treatment. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-021-08983-2.
format Online
Article
Text
id pubmed-8605535
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-86055352021-11-22 Association between oligo-residual disease and patterns of failure during EGFR-TKI treatment in EGFR-mutated non-small cell lung cancer: a retrospective study Miyawaki, Taichi Kenmotsu, Hirotsugu Kodama, Hiroaki Nishioka, Naoya Miyawaki, Eriko Mamesaya, Nobuaki Kobayashi, Haruki Omori, Shota Ko, Ryo Wakuda, Kazushige Ono, Akira Naito, Tateaki Murakami, Haruyasu Mori, Keita Harada, Hideyuki Endo, Masahiro Takahashi, Kazuhisa Takahashi, Toshiaki BMC Cancer Research BACKGROUND: Local ablative therapy (LAT) may be beneficial for patients with epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer (NSCLC) with oligo-residual disease after treatment with EGFR tyrosine kinase inhibitor (EGFR-TKI). However, this has not been fully established. This study aimed to evaluate the predominant progressive disease (PD) pattern limited to residual sites of disease after treatment with EGFR-TKI. METHODS: Patients with advanced EGFR-mutated NSCLC treated with EGFR-TKIs as first-line therapy were retrospectively analysed during a 7-year period. Oligo-residual disease was defined as the presence of 1 – 4 lesions (including the primary site) at 3 months from the start of EGFR-TKI treatment. The predictive factors of PD patterns after EGFR-TKI treatment were evaluated. RESULTS: A total of 207 patients were included. Three months after the start of EGFR-TKI treatment, 66 patients (32%) had oligo-residual disease. A total of 191 patients had PD, 60 with oligo-residual disease and 131 with non-oligo-residual disease. Regarding the pattern, 44 patients (73%) with oligo-residual disease and 37 patients (28%) with non-oligo-residual disease had PD limited to the residual sites. Multivariate logistic regression analysis at 3 months from the start of EGFR-TKI treatment revealed that oligo-residual disease (P < 0.001), the lack of residual central nervous system metastases (P = 0.032), and initial treatment with osimertinib (P = 0.028) were independent predictors of PD limited to residual disease sites. CONCLUSIONS: This study provided a rationale for LAT to all sites of residual disease in patients with oligo-residual disease during EGFR-TKI treatment. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-021-08983-2. BioMed Central 2021-11-19 /pmc/articles/PMC8605535/ /pubmed/34798865 http://dx.doi.org/10.1186/s12885-021-08983-2 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Miyawaki, Taichi
Kenmotsu, Hirotsugu
Kodama, Hiroaki
Nishioka, Naoya
Miyawaki, Eriko
Mamesaya, Nobuaki
Kobayashi, Haruki
Omori, Shota
Ko, Ryo
Wakuda, Kazushige
Ono, Akira
Naito, Tateaki
Murakami, Haruyasu
Mori, Keita
Harada, Hideyuki
Endo, Masahiro
Takahashi, Kazuhisa
Takahashi, Toshiaki
Association between oligo-residual disease and patterns of failure during EGFR-TKI treatment in EGFR-mutated non-small cell lung cancer: a retrospective study
title Association between oligo-residual disease and patterns of failure during EGFR-TKI treatment in EGFR-mutated non-small cell lung cancer: a retrospective study
title_full Association between oligo-residual disease and patterns of failure during EGFR-TKI treatment in EGFR-mutated non-small cell lung cancer: a retrospective study
title_fullStr Association between oligo-residual disease and patterns of failure during EGFR-TKI treatment in EGFR-mutated non-small cell lung cancer: a retrospective study
title_full_unstemmed Association between oligo-residual disease and patterns of failure during EGFR-TKI treatment in EGFR-mutated non-small cell lung cancer: a retrospective study
title_short Association between oligo-residual disease and patterns of failure during EGFR-TKI treatment in EGFR-mutated non-small cell lung cancer: a retrospective study
title_sort association between oligo-residual disease and patterns of failure during egfr-tki treatment in egfr-mutated non-small cell lung cancer: a retrospective study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8605535/
https://www.ncbi.nlm.nih.gov/pubmed/34798865
http://dx.doi.org/10.1186/s12885-021-08983-2
work_keys_str_mv AT miyawakitaichi associationbetweenoligoresidualdiseaseandpatternsoffailureduringegfrtkitreatmentinegfrmutatednonsmallcelllungcanceraretrospectivestudy
AT kenmotsuhirotsugu associationbetweenoligoresidualdiseaseandpatternsoffailureduringegfrtkitreatmentinegfrmutatednonsmallcelllungcanceraretrospectivestudy
AT kodamahiroaki associationbetweenoligoresidualdiseaseandpatternsoffailureduringegfrtkitreatmentinegfrmutatednonsmallcelllungcanceraretrospectivestudy
AT nishiokanaoya associationbetweenoligoresidualdiseaseandpatternsoffailureduringegfrtkitreatmentinegfrmutatednonsmallcelllungcanceraretrospectivestudy
AT miyawakieriko associationbetweenoligoresidualdiseaseandpatternsoffailureduringegfrtkitreatmentinegfrmutatednonsmallcelllungcanceraretrospectivestudy
AT mamesayanobuaki associationbetweenoligoresidualdiseaseandpatternsoffailureduringegfrtkitreatmentinegfrmutatednonsmallcelllungcanceraretrospectivestudy
AT kobayashiharuki associationbetweenoligoresidualdiseaseandpatternsoffailureduringegfrtkitreatmentinegfrmutatednonsmallcelllungcanceraretrospectivestudy
AT omorishota associationbetweenoligoresidualdiseaseandpatternsoffailureduringegfrtkitreatmentinegfrmutatednonsmallcelllungcanceraretrospectivestudy
AT koryo associationbetweenoligoresidualdiseaseandpatternsoffailureduringegfrtkitreatmentinegfrmutatednonsmallcelllungcanceraretrospectivestudy
AT wakudakazushige associationbetweenoligoresidualdiseaseandpatternsoffailureduringegfrtkitreatmentinegfrmutatednonsmallcelllungcanceraretrospectivestudy
AT onoakira associationbetweenoligoresidualdiseaseandpatternsoffailureduringegfrtkitreatmentinegfrmutatednonsmallcelllungcanceraretrospectivestudy
AT naitotateaki associationbetweenoligoresidualdiseaseandpatternsoffailureduringegfrtkitreatmentinegfrmutatednonsmallcelllungcanceraretrospectivestudy
AT murakamiharuyasu associationbetweenoligoresidualdiseaseandpatternsoffailureduringegfrtkitreatmentinegfrmutatednonsmallcelllungcanceraretrospectivestudy
AT morikeita associationbetweenoligoresidualdiseaseandpatternsoffailureduringegfrtkitreatmentinegfrmutatednonsmallcelllungcanceraretrospectivestudy
AT haradahideyuki associationbetweenoligoresidualdiseaseandpatternsoffailureduringegfrtkitreatmentinegfrmutatednonsmallcelllungcanceraretrospectivestudy
AT endomasahiro associationbetweenoligoresidualdiseaseandpatternsoffailureduringegfrtkitreatmentinegfrmutatednonsmallcelllungcanceraretrospectivestudy
AT takahashikazuhisa associationbetweenoligoresidualdiseaseandpatternsoffailureduringegfrtkitreatmentinegfrmutatednonsmallcelllungcanceraretrospectivestudy
AT takahashitoshiaki associationbetweenoligoresidualdiseaseandpatternsoffailureduringegfrtkitreatmentinegfrmutatednonsmallcelllungcanceraretrospectivestudy